Open AccessAssessment of the application for renewal of authorisation of Biosprint ® ( Saccharomyces cerevisiae MUCL 39885) as a feed additive for weaned piglets
Author(s) -
Bampidis Vasileios,
Azimonti Giovanna,
Bastos Maria de Lourdes,
Christensen Henrik,
Dusemund Birgit,
Kos Durjava Mojca,
Kouba Maryline,
LópezAlonso Marta,
López Puente Secundino,
Marcon Francesca,
Mayo Baltasar,
Pechová Alena,
Petkova Mariana,
Ramos Fernando,
Sanz Yolanda,
Villa Roberto Edoardo,
Woutersen Ruud,
Anguita Montserrat,
Galobart Jaume,
Holczknecht Orsolya,
Manini Paola,
TarrésCall Jordi,
Pettenati Elisa,
Pizzo Fabiola
Publication year - 2020
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2020.6284
Subject(s) - authorization , context (archaeology) , european commission , feed additive , microbiology and biotechnology , toxicology , food science , european union , business , medicine , biology , economic policy , paleontology , computer security , broiler , computer science
Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed ( FEEDAP ) was asked to deliver a scientific opinion on the assessment of the application for renewal of the authorisation of the product Biosprint ® ( Saccharomyces cerevisiae MUCL 39885) as a feed additive for weaned piglets. Biosprint ® is composed of only viable cells of Saccharomyces cerevisiae MUCL 39885. S. cerevisiae is considered by EFSA to have qualified presumption of safety status. The applicant has provided data demonstrating that the additive currently in the market complies with the conditions of the authorisation. The FEEDAP Panel confirms that the use of Biosprint ® under the current authorised conditions of use is safe for weaned piglets, the consumers and the environment. The additive is considered as a potential skin and eye irritant and a skin and respiratory sensitiser. There is no need to assess the efficacy of Biosprint ® in the context of the renewal of the authorisation.